Medexus to Present at The LD Micro Virtual Invitational XI on June 8th
Medexus Pharmaceuticals, listed as OTCQX: MEDXF, announced their participation in the LD Micro Invitational XI investor conference from June 8-10, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Medexus Pharmaceuticals, listed as OTCQX: MEDXF, announced their participation in the LD Micro Invitational XI investor conference from June 8-10, 2021. CEO Ken d’Entremont and CFO Roland Boivin will present on June 8 at 12:30 p.m. EST. The conference provides a platform for investors to gain insights into Medexus's growth strategy in the rare disease market. Medexus focuses on innovative therapies for auto-immune diseases, hematology, and allergies, with prominent products like Rasuvo™, IXINITY®, and Rupall®.
Details
News Market Reaction – MEDXF
The recorded move for MEDXF in the trading session of this news was +1.65%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
TORONTO and CHICAGO and MONTREAL, June 01, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQX: MEDXF), today announced that management will present at the LD Micro Invitational XI investor conference taking place virtually June 8-10, 2021.
Ken d’Entremont, Chief Executive Officer of Medexus, and Roland Boivin, Chief Financial Officer of Medexus, are scheduled to host a virtual presentation to investors during the event as follows:
2021 LD Micro Invitational XI
Date: Tuesday, June 8, 2021
Time: 12:30 p.m. EST – Track 1
Webcast: Sequire | Virtual Events (mysequire.com)
For more information on the LD Micro Invitational XI, or to register for the event, please visit https://ldmicrojune2021.mysequire.com.
About Medexus Pharmaceuticals Inc.
Medexus is a leading innovative and rare disease company with a strong North American commercial platform. From a foundation of proven best in class products we are building a highly differentiated company with a portfolio of innovative and high value orphan and rare disease products that will underpin our growth for the next decade. The Company’s vision is to provide the best healthcare products to healthcare professionals and patients, through our core values of Quality, Innovation, Customer Service and Teamwork. Medexus Pharmaceuticals is focused on the therapeutic areas of auto-immune disease, hematology, and allergy. The Company’s leading products are: Rasuvo™ and Metoject®, a unique formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY®, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B – a hereditary bleeding disorder characterized by a deficiency of clotting factor IX in the blood, which is necessary to control bleeding; and Rupall®, an innovative prescription allergy medication with a unique mode of action.
MEDEXUS CONTACTS:
Ken d’Entremont, Chief Executive Officer
Medexus Pharmaceuticals Inc.
Tel.: 905-676-0003
E-mail: ken.dentremont@medexus.com
Roland Boivin, Chief Financial Officer
Medexus Pharmaceuticals Inc.
Tel.: 514-762-2626 ext. 202
E-mail: roland.boivin@medexus.com
Investor Relations (U.S.):
Crescendo Communications, LLC
Tel: +1-212-671-1020
Email: mdp@crescendo-ir.com
Investor Relations (Canada):
Tina Byers
Adelaide Capital
Tel: 905-330-3275
E-mail: tina@adcap.ca
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.